



			Stage of Development			
Product	Disease Target	Technology Alliances	Early	Late	Filed	Approved
DERMATOLOGY						
Tazarotene Oral (U.S.)	Moderate to Severe Psoriasis		•	•	•	
AVAGE (U.S./Europe)	Photodamage		•	• (E.U.)	•	• (U.S.)
Peplin (PEP005)	Actinic Keratosis	Peplin Biotech Ltd.	•			
Peplin (PEP005)	Basal and Squamous Cell Carcinoma	Peplin Biotech Ltd.	•			
NEW TECHNOLOGY						
AGN 201904 (Proton Pump Inhibitor)	Gastric Ulcers	Winston Pharmaceuticals	•			
AGN 199981 & 201781 (Alpha Agonist)	Neural / Visceral Pain		•			
AGN 203818 (Alpha Agonist)	Neural / Visceral Pain		•			
Product	Disease Target	Company Alliances				
COLLABORATIONS						
Alpha Agonists	Glaucoma / Neuropathic Pain	Acadia Pharmaceuticals, Inc.				
Muscarinics	Glaucoma	Acadia Pharmaceuticals, Inc.				
AZELEX	Acne	Berlex, Inc.				
Compound Screening Library	General R&D	Discovery Partners				
Neuromodulators	Pain	Centre for Applied Microbiology & Research (CAMR)				
Panzem	Age Related Macular Degeneration (ARMD)	EntreMed, Inc.				
Drug Target Identification	Pain, Ophthalmology and Neurology	ExonHit Therapeutics				
ELESTAT	Allergy	Inspire Pharmaceuticals, Inc.				
ALOCRIL	Allergy	Procter & Gamble Pharmaceuticals, Inc. – General Practitioners (Canada)				
TAZORAC Gel and Cream	Psoriasis and Acne	Procter & Gamble Pharmaceuticals, Inc. – General Practitioners (U.S./Canada)				
ZORAC Gel	Psoriasis and Acne	Pierre Fabre Dermatologie (Europe)				
OCUFLOX	Anti-Infective	Daiichi/Santen				

Health care product development is an uncertain process. Products reach market only after meeting specific criteria for efficacy and safety. There can be no assurance that any product undergoing clinical trials or pending regulatory approvals will be marketed.

This pharmaceutical pipeline includes products developed by Allergan and products for which Allergan has marketing rights.